Status:
RECRUITING
Improving Patient-reported Outcomes After Lung Cancer Surgery With Mobile Internet Platform
Lead Sponsor:
Shanghai Chest Hospital
Conditions:
Lung Cancer
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
This study focuses on the significant impact of lung cancer in China, highlighted by its high incidence and mortality rates, influenced by factors like aging populations, smoking, and environmental is...
Detailed Description
Lung cancer is the leading cause of cancer-related deaths worldwide. In China, it has become the malignancy with the highest incidence and mortality rates, exacerbated by aging populations, smoking, a...
Eligibility Criteria
Inclusion
- Diagnosed with Stage I-III lung cancer and surgically resected at our centre.
- Owns and uses a smartphone and can use WeChat.
- Volunteer to participate in this study and sign an informed consent form.
Exclusion
- Received any non-surgical anti-tumour therapy (radiotherapy, chemotherapy, targeted therapy or immunotherapy) for lung cancer during the follow-up period.
- After enrolment, preoperative emergence of serious comorbidities (inability to tolerate surgery or anaesthesia) that are not suitable for, or cannot be implemented as planned, in the study's treatment regimen.
- After admission, the patient's condition changes and the need to change from elective surgery to emergency surgery is confirmed by the doctor in charge.
- At any stage after entering the study, the patient voluntarily requests to withdraw or discontinue treatment due to personal reasons.
Key Trial Info
Start Date :
March 24 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
216 Patients enrolled
Trial Details
Trial ID
NCT06483295
Start Date
March 24 2024
End Date
December 31 2026
Last Update
May 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zuodong Song
Shanghai, Shanghai Municipality, China, 200030